NY-ESO-1 protein expression and humoral immune responses in prostate cancer

Prostate. 2004 Jun 1;59(4):440-7. doi: 10.1002/pros.20025.


Background: Due to restricted expression in normal tissues cancer/testis (C/T) antigens represent candidate molecules for immunotherapy of cancer. NY-ESO-1 is a well-studied C/T antigen with unknown expression and immunogenicity in prostate cancer (PC) patients.

Methods: NY-ESO-1 expression was determined by immunohistochemistry and humoral immune responses against NY-ESO-1 assessed by enzyme-linked immuno-sorbent assay (ELISA) and Western blotting. Protein expression and serological responses were correlated with clinical findings and survival.

Results: NY-ESO-1 expression was found in biopsies from 2 of 66 localized PC and 7/48 hormone refractory prostate cancer (HRPC) patients, respectively. Anti-NY-ESO-1 antibodies were detected in sera from 1 of 112 localized PC and 18 of 95 HRPC patients. Two of four HRPC patients with NY-ESO-1 positive biopsies had mounted a serological response. Positive anti-NY-ESO-1 titers were correlated with poor survival in HRPC patients.

Conclusions: NY-ESO-1 is expressed in a subset of HRPC patients and, together with other C/T antigens, may serve as a target antigen for development of immunotherapy of PC. Spontaneous serological responses against NY-ESO-1 may be associated with poor survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibody Formation*
  • Antigens, Neoplasm / biosynthesis*
  • Antigens, Neoplasm / immunology*
  • Blotting, Western
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunoglobulin G / analysis
  • Immunohistochemistry
  • Immunotherapy
  • Male
  • Membrane Proteins / biosynthesis*
  • Membrane Proteins / immunology*
  • Middle Aged
  • Prognosis
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / immunology*
  • Survival Analysis
  • Testis


  • Antigens, Neoplasm
  • CTAG1B protein, human
  • Immunoglobulin G
  • Membrane Proteins